Revolution Medicines RMC-6236 RAS Inhibitor 2023

Presentation on RMC-6236, a novel first-in-class RASMULTI(ON) inhibitor for KRAS-mutant solid tumors, featuring preliminary clinical results from the Phase 1/1b RMC-6236-001 trial. Delivered by Dr. Brian Wolpin of Dana-Farber Cancer Institute at a Hanson Wade meeting in September 2023.